Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Mirum Pharmaceuticals (MIRM) Gross Margin (2023 - 2025)

Mirum Pharmaceuticals has reported Gross Margin over the past 3 years, most recently at 81.02% for Q4 2025.

  • Quarterly results put Gross Margin at 81.02% for Q4 2025, up 394.0% from a year ago — trailing twelve months through Dec 2025 was 80.77% (up 501.0% YoY), and the annual figure for FY2025 was 80.77%, up 501.0%.
  • Gross Margin for Q4 2025 was 81.02% at Mirum Pharmaceuticals, roughly flat from 80.8% in the prior quarter.
  • Over the last five years, Gross Margin for MIRM hit a ceiling of 84.24% in Q1 2023 and a floor of 64.03% in Q4 2023.
  • Median Gross Margin over the past 3 years was 78.97% (2023), compared with a mean of 77.82%.
  • Peak annual rise in Gross Margin hit 1306bps in 2024, while the deepest fall reached -1000bps in 2024.
  • Mirum Pharmaceuticals' Gross Margin stood at 64.03% in 2023, then increased by 20bps to 77.09% in 2024, then rose by 5bps to 81.02% in 2025.
  • The last three reported values for Gross Margin were 81.02% (Q4 2025), 80.8% (Q3 2025), and 81.67% (Q2 2025) per Business Quant data.